2003, Biopharma and Food and Drug Administration

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Biopharma

Food and Drug Administration

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

OCTOBER 19, 2023

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. There have been many cases where people have tried to simply link existing drugs to radioisotopes or have attached new (recently made in scale) radioisotopes on old drugs.

Food and Drug Administration

Food and Drug Administration Manufacturing Side effects Doctors

Innovations & Challenges in Brain Health

PM360

NOVEMBER 12, 2024

They are difficult to diagnose early in a disease, the regulatory endpoints are often unprecedented and challenging, and many drugs struggle to get into the brain. The downside is that it also keeps most potential drug treatments from reaching the brain. Not surprisingly, several companies have been in and out of brain health diseases.

Food and Drug Administration

Food and Drug Administration Healthcare Provider Healthcare Healthcare

Pharma Rep Focus

Targeting tumours with novel radiopharmaceuticals

Innovations & Challenges in Brain Health

Stay Connected